Charlotte Rawcliffe

4.2k total citations
12 papers, 244 citations indexed

About

Charlotte Rawcliffe is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Charlotte Rawcliffe has authored 12 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Cancer Research and 3 papers in Surgery. Recurrent topics in Charlotte Rawcliffe's work include Pancreatic and Hepatic Oncology Research (9 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Charlotte Rawcliffe is often cited by papers focused on Pancreatic and Hepatic Oncology Research (9 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Charlotte Rawcliffe collaborates with scholars based in United Kingdom, Germany and Australia. Charlotte Rawcliffe's co-authors include Daniel H. Palmer, John P. Neoptolemos, Paula Ghaneh, Markus W. Büchler, Christopher Halloran, Harpreet Wasan, Jonathan Wadsley, Somnath Mukherjee, Janet S. Graham and Eftychia Eirini Psarelli and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Charlotte Rawcliffe

11 papers receiving 244 citations

Peers

Charlotte Rawcliffe

ONCOL

PRM

SURGE

EPIDE

Alejandra Ragone Canada

Aude Bardot France

Jewel Samadder United States

Nalinie Joharatnam‐Hogan United Kingdom

Sara Koo United Kingdom

Marjan van Hezewijk Netherlands

Elizabeth Hodgkinson United Kingdom

Timur Mitin United States

Pooja Prabhakar United States

Anton Gies Germany

Alejandra Ragone Canada

Charlotte Rawcliffe

135 ×0.7

ONCOL

89 ×1.0

60 ×0.7

PRM

24 ×0.4

SURGE

41 ×0.9

EPIDE

Citations per year, relative to Charlotte Rawcliffe Charlotte Rawcliffe (= 1×) peers Alejandra Ragone

Countries citing papers authored by Charlotte Rawcliffe

Since Specialization

Citations

This map shows the geographic impact of Charlotte Rawcliffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte Rawcliffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte Rawcliffe more than expected).

Fields of papers citing papers by Charlotte Rawcliffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte Rawcliffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte Rawcliffe. The network helps show where Charlotte Rawcliffe may publish in the future.

Co-authorship network of co-authors of Charlotte Rawcliffe

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte Rawcliffe. A scholar is included among the top collaborators of Charlotte Rawcliffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte Rawcliffe. Charlotte Rawcliffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Ghaneh, Paula, Daniel H. Palmer, Silvia Cicconi, et al.. (2020). ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.. Journal of Clinical Oncology. 38(15_suppl). 4505–4505. 110 indexed citations

Ghaneh, Paula, Daniel H. Palmer, Silvia Cicconi, et al.. (2020). ESPAC-5F: Four arm, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. Pancreatology. 20. S4–S5. 4 indexed citations

Evans, A.G., Colin Jones, James S. Hale, et al.. (2020). Enrichment of circulating tumour cells by dielectrophoresis in pancreatic ductal adenocarcinoma. Pancreatology. 20. S131–S131.

Nathan, Paul, Sarah Danson, Jonathan J. Evans, et al.. (2019). SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology. 30. v908–v910. 10 indexed citations

Duley, Lelia, Alexa Gillman, Marian Duggan, et al.. (2018). What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK. Trials. 19(1). 15–15. 36 indexed citations

Palmer, Daniel H., Paul J. Ross, Paul Silcocks, et al.. (2018). ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. Journal of Clinical Oncology. 36(4_suppl). TPS537–TPS537. 5 indexed citations

Evans, A.G., Richard Jackson, Victoria Shaw, et al.. (2018). Biomarker predication of efficacy to gemcitabine plus vandetanib in phase II, double blind multicentre randomised controlled trial of gemcitabine placebo in locally advanced or metastatic pancreatic carcinoma. Pancreatology. 18(4). S127–S128. 1 indexed citations

Neoptolemos, John P., Daniel H. Palmer, William Greenhalf, et al.. (2017). Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo-controlled trial in locally advanced or metastatic pancreatic carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 4104–4104. 1 indexed citations

Kleeff, Jörg, Eithne Costello, Richard Jackson, et al.. (2016). The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. British Journal of Cancer. 115(7). 887–894. 46 indexed citations

10.

Neoptolemos, John P., William Greenhalf, Paula Ghaneh, et al.. (2013). HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. Journal of Clinical Oncology. 31(15_suppl). 4006–4006. 14 indexed citations

11.

Neoptolemos, John P., Malcolm J. Moore, Trevor F. Cox, et al.. (2011). Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.. Journal of Clinical Oncology. 29(18_suppl). LBA4006–LBA4006. 14 indexed citations

12.

Neoptolemos, John P., et al.. (2011). Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.. Journal of Clinical Oncology. 29(15_suppl). LBA4006–LBA4006. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact